2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-105793
    Mazaticol 42024-98-6 98%
    Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research.
    Mazaticol
  • HY-105844
    Albutoin 830-89-7 99.17%
    Albutoin (BAX 422Z), an anticonvulsant agent, is a thiohydantoin derivative used for the research of grand mal epilepsies.
    Albutoin
  • HY-105845
    Phenaglycodol 79-93-6 98%
    Phenaglycodol belongs to the group of butanediolsa with anxiolytic and anticonvulsant porperties. Phenaglycodol has orally bioactivity.
    Phenaglycodol
  • HY-105852
    Proxazole 5696-09-3 98%
    Proxazole (Propoxaline) is an anti-inflammatory agent. Proxazole prevents Indomethacin (HY-14397)-induced ulcers without anti-secretory effect. Proxazole is also a spasmolytic papaverine-like agent.
    Proxazole
  • HY-105853
    Pitofenone 54063-52-4 98%
    Pitofenone, a spasmolytic compound, inhibits the acetylcholinesterase (AChE) activity from bovine erythrocytes and from electric eel with Kis of 36 and 45 μM, respectively.
    Pitofenone
  • HY-10585B
    Valproic acid sodium (2:1) 76584-70-8 98%
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium (2:1)
  • HY-105911
    Org 6582 59905-71-4 98%
    Org 6582 is a competitive, selective, and long-acting 5-HT (Ki = 89 nM) uptake inhibitor. Org 6582’s inhibitory effect on 5-HT uptake can last for more than 48 hours. Org 6582 can be used for research on depressive disorders.
    Org 6582
  • HY-105998
    AVN-211 1173103-84-8 98%
    AVN-211 (CD-008-0173) is a selective and orally active 5HT6R antagonist with an IC50 of 2.34 nM and a Ki of 1.09 nM. AVN-211 exhibits 5K-fold higher 5HT6R selectivity over other 65 receptors, enzymes, and ion channels. AVN-211 significantly improves cognitive and anxiety behaviors in various AD animal models, and has good safety profiles. AVN-211 can be used for the study of Alzheimer's dementia.
    AVN-211
  • HY-106010
    LBP1 1050478-18-6 98%
    LBP1 is an orally active and low brain penetrant CB1 receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain.
    LBP1
  • HY-106039
    LY 215490 150010-68-7 98%
    LY 215490 is a selective, competitive AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC50 values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia.
    LY 215490
  • HY-106075
    Bromerguride 83455-48-5 98%
    Bromerguride (2-Bromolisuride) is an analogue of the ergot dopamine agonist Lisuride (HY-12713). Bromerguride exhibits central antidopaminergic properties.
    Bromerguride
  • HY-106079
    Fezolamine 80410-36-2 98%
    Fezolamine is an orally active non-tricyclic compound , and shows antidepressant activity.
    Fezolamine
  • HY-106100
    Roxindole 112192-04-8 98%
    Roxindole (EMD 49980), an indot-alkyl-pipenidine, is a potent agonist at dopamine autoreceptors, with an affinity for the D2-like subtype in the low nanomolar range. Roxindole can be used for the research of positive and negative schizophrenic symptoms. Roxindole is a 5-HT1A agonist and 5-HT uptake inhibitor. Antipsychotic and antidepressant activities.
    Roxindole
  • HY-106103
    Seglitide 81377-02-8 99.30%
    Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes.
    Seglitide
  • HY-106136
    TIK-301 118702-11-7 98%
    TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT1 and MT2 receptors agonist with Kis of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT2B/5-HT2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment.
    TIK-301
  • HY-106137
    Tofimilast 185954-27-2 98%
    Tofimilast is an inhibitor of Phosphodiesterase 4 (PDE4) with an IC50 of 0.14 μM. Tofimilast exerts its anti-inflammatory effects by inhibiting the activity of PDE4, thereby increasing intracellular levels of cAMP.
    Tofimilast
  • HY-106143
    Belaperidone 208661-17-0 98%
    Belaperidone (LU-111995), a 5-HT2A receptor inhibitor, possesses antidopaminergic and antiserotonergic effects.
    Belaperidone
  • HY-106147
    Frakefamide 188196-22-7 98%
    Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.
    Frakefamide
  • HY-106180
    DTI 0009 110299-05-3 98%
    DTI 0009 is a selective adenosine A1 receptor agonist used to reduce heart rate in patients with atrial fibrillation and to treat arrhythmias.
    DTI 0009
  • HY-106186
    GW-493838 253124-46-8 98%
    GW-493838 is a potent Adenosine A1 (A1AR) agonist. GW-493838 has the potential for the research of neuropathic pain.
    GW-493838
Cat. No. Product Name / Synonyms Application Reactivity